News Posts List
Megstrong Benefit for Meagan Blackmore
06/12/2013
Meagan Blackmore was diagnosed with stage four kidney cancer at the age of 30. This June 20th fundraiser event in Albany, NY will help raise money to help Megstrong and Meagan's fight against kidney cancer. For more information on this event or this organization, please visit: http://www.megstrong.com/
Secondary Cancers: More Common Than You Think
06/12/2013
A funny thing happened when I was hospitalized recently for pneumonia in both lungs. Not funny as in laugh-out-loud, but funny as in weird.
Researchers test safety of Nivolumab in kidney cancer
06/12/2013
Researchers at Dartmouth-Hitchcock Norris Cotton Cancer Center presented a poster on a phase I clinical trial of Nivolumab, a PD-1 receptor blocking antibody, being used in combination with other drugs in patients with metastatic renal cell carcinoma (mRCC) at the ASCO Annual Meeting on June 3, 2013.
Argos Therapeutics Announces US and Global Expansion for Ongoing Pivotal Phase 3 ADAPT Study
06/12/2013
Argos Therapeutics Inc., a biopharmaceutical company focused on the development and commercialization of fully personalized immunotherapies for the treatment of cancer and infectious diseasesusing its Arcelis(TM) technology platform, today announced it has expanded its ADAPT Phase 3 clinical study for AGS-003.
Bionomics Completes Enrolment for BNC105 Phase II Renal Cancer Trial
06/12/2013
Bionomics Limited (ASX:BNO) has completed enrolment into a randomized Phase II clinical trial testing the combination of BNC105 plus everolimus (Afinitor) to treat patients with advanced renal cell carcinoma, the DisrupTOR-1 clinical trial.
Immunomedics Develops Novel Dual System for Tumor Detection and Imaging
06/11/2013
Immunomedics, Inc. (IMMU), a biopharmaceutical company primarily focused on the development of monoclonal antibody-based products for the targeted treatment of cancer, autoimmune and other serious diseases, today announced the development of a pretargeting system that can detect and optically image a tumor during surgery.
Bionomics Completes Enrolment for BNC105 Phase II Renal Cancer Trial
06/11/2013
Bionomics Limited (ASX:BNO) has completed enrolment into a randomized Phase II clinical trial testing the combination of BNC105 plus everolimus (Afinitor) to treat patients with advanced renal cell carcinoma, the DisrupTOR-1 clinical trial.
Argos Therapeutics Announces US and Global Expansion for Ongoing Pivotal Phase 3 ADAPT Study
06/11/2013
Argos Therapeutics Inc., a biopharmaceutical company focused on the development and commercialization of fully personalized immunotherapies for the treatment of cancer and infectious diseases using its Arcelis(TM) technology platform, today announced it has expanded its ADAPT Phase 3 clinical study for AGS-003 to additional top cancer centers in the United States, Canada and will soon be expanding into Europe and Israel.
Advancing Critical Pathways Forward in the Treatment of Colorectal and Kidney Cancer
06/10/2013
The Angiogenesis Foundation will release two new white papers, in conjunction with the American Society of Clinical Oncology (ASCO) Annual Meeting, which address the needs, challenges, and proposed solutions to improve outcomes in two of the top ten most common cancers in the United States: metastatic colorectal cancer (mCRC) and renal cell carcinoma (RCC), also known as kidney cancer.
Common solvent linked to cancer risk
06/08/2013
Scandinavian workers exposed to a common industrial cleaning fluid showed higher risk for developing cancers of the liver, kidneys and cervix in a large new study.
News Feed